Balancing Method for Pain Related to Advanced Cancer

NCT04176575 | Completed DMC

• 1 other identifier: STUDY18120017
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

Balancing Method for Pain Related to Advanced Cancer seeks to confirm the benefit of acupuncture for patients with pain related to advanced cancer.

Conditions

Pain, Cancer; Metastatic Cancer; Invasive Cancer

Keywords

Acupuncture; Cancer Pain

Outcome Measures

Primary Outcomes (14)

• Measuring effectiveness of acupuncture by assessing change in pain ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Numeric Rating Scale v.1.0 - Pain Intensity 1a (NRS)

  Participant report of pain on average on a scale from 'no pain' (0) to "worst imaginable pain" (10). Higher scores mean worse outcome.

  Baseline, each visit; up to 18 weeks (per participant)

• Measuring effectiveness of acupuncture by assessing change in pain intensity ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Pain Intensity Scale

  Participant report of symptoms in the past week on a scale from "no pain" (1) to "very severe" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.

  Baseline, each week, at follow-up; up to 18 weeks (per participant)

• Measuring effectiveness of acupuncture by assessing change in pain interference ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Pain Interference Short Form 4a

  Participant report of symptoms in the past week on a scale from "not at all" (1) to "very much" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.

  Baseline, each week, at follow-up; up to 18 weeks (per participant)

• Measuring effectiveness of acupuncture by assessing change in fatigue ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Fatigue Short Form 4a

  Participant report of symptoms in the past week on a scale from "not at all" (1) to "very much" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.

  Baseline, each week, at follow-up; up to 18 weeks (per participant)

• Measuring effectiveness of acupuncture by assessing change in anxiety symptom ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Emotional Distress-Anxiety - Short Form 4a

  Participant report of symptoms in the past week on a scale from "never" (1) to "always" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.

  Baseline, each week, at follow-up; up to 18 weeks (per participant)

• Measuring effectiveness of acupuncture by assessing change in sleep disturbance ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Sleep Disturbance - Short Form 4a

  Participant report of symptoms in the past week on a scale from "very poor/very much" (1) to "very good/not at all" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.

  Baseline, each week, at follow-up; up to 18 weeks (per participant)

• Measuring effectiveness of acupuncture by assessing change in gastrointestinal symptom ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Gastrointestinal Nausea and Vomiting

  Participant report of symptoms in the past week on a scale from "never" (1) to "always" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.

  Baseline, each week, at follow-up; up to 18 weeks (per participant)

• Measuring effectiveness of acupuncture by assessing improvement in global symptoms ratings at Week 4 and Weeks 9-12 and 4 week follow-up using Patient Global Index of Change: Improvement (PGIC-I)

  Participant rating of symptom severity on a scale of -2 (much better) to 2 (much worse). Higher scores mean worse outcome. This measure assesses changes in symptoms over the course of study participation.

  Week 5, Weeks 9-12 and follow-up; up to 18 weeks (per participant)

• Measuring health intervention attitudes and beliefs at start of study by using Healing Encounters Attitudes List Measures: Treatment Expectancy (HEAL-TEX)

  Participant report of treatment expectancy on a 5 point scale (1-5) ranging from "Not at all" (1) to "Very much" (5). Higher scores ("Very much") indicate higher treatment expectancy.

  Baseline Visit

• Measuring perception of effectiveness based on patient-provider connections by using Healing Encounters Attitudes List: Perception of the Patient-Provider Connection (HEAL-PPC)

  Participant report of the patient-provider connection on a 5 point scale ranging from "Not at all" to "Very much". Higher scores ("Very much") mean better outcome. This measure assesses a change in the patient-provider connection from the beginning of study participation to the end.

  Week 4 and Weeks 9, 10, 11, 12

• Measuring spiritual attitudes and beliefs at start of study by using Healing Encounters Attitudes List Measures: Spirituality (HEAL-SPT)

  Participant report of Spirituality on a 5 point scale (1-5) ranging from "Not at all" (1) to "Very much" (5). Higher scores ("Very much") indicate higher personal spiritual belief.

  Baseline Visit

• Monitoring and recording use of opioids throughout the study protocol using Opioid Use Questionnaire

  Internally-developed, participant report of pain medication use. This questionnaire collects dosing/frequency information, which is used to calculate morphine equivalent dosing (MED). This information will be used to assess change in pain medication use over the course of study participation.

  Baseline; weekly; follow-up; up to 18 weeks (per participant)

• Assessing for treatment-related adverse events as recorded by Acupuncture Safety Record

  Internally-developed, participant report of acupuncture related adverse events. Administered in a checklist form. More selections on this form means more acupuncture related adverse events.

  Baseline; each visit and follow-up; up to 18 weeks (per participant)

• Assessing for treatment-related and illness-related symptoms as recorded by Symptoms Checklist (SC)

  Captures new or worsening health problems participants have experienced since their last study visit. More selections on this form means worse outcome.

  Baseline; each visit and follow-up; up to 18 weeks (per participant)

Study Arms (1)

Acupuncture

EXPERIMENTAL

Eligible participants: * have advanced stage cancer and associated pain * will receive up to 12 acupuncture sessions * will attend sessions at UPMC's Center for Integrative Medicine * will complete study assessments at each visit * will complete a follow-up 4 to 6 weeks after their last acupuncture visit. Total study involvement will range from 16 to 18 weeks.

Other: Acupuncture

Interventions

Acupuncture OTHER

Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.

Acupuncture

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 or older.
• Current diagnosis of a malignancy.
• Locally invasive, metastatic, or systemic involvement from the disease, which would be anticipated to produce pain.
• Average pain level, on a numeric rating scale, of 4/10 or higher on the Numeric Rating Scale (NRS).
• Receiving treatment through Hillman Cancer Center, Magee Hospital, or 1 of the University of Pittsburgh Cancer Institute sites.
• Able to read and write English.

You may not qualify if:

• Experience with acupuncture within the prior 3 months.
• Platelet count \< 50,000.
• Absolute Neutrophil Count \< 1,000.
• Treatment with anticoagulant medication, other than prophylactic levels of heparin or low molecular weight heparin preparations or anti-platelet agents.
• Known coagulopathy.

Sponsors & Collaborators

• University of Pittsburgh: lead

Study Sites (1)

UPMC Center for Integrative Medicine

Pittsburgh, Pennsylvania, 15218, United States

Location

MeSH Terms

Conditions

Cancer Pain; Neoplasm Metastasis

Interventions

Acupuncture Therapy

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Neoplastic Processes; Neoplasms; Pathologic Processes

Intervention Hierarchy (Ancestors)

Complementary Therapies; Therapeutics

Study Officials

• Ronald M Glick, MD

  Hillman Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Model Details: This clinical trial is a descriptive, interventional, and open-label pilot study.

Study Record Dates

• First Submitted: November 1, 2019
• First Posted: November 25, 2019
• Study Start: July 5, 2022
• Primary Completion: December 20, 2023
• Study Completion: January 20, 2024
• Last Updated: January 24, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)